Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Additional phase III data in support of TTFC

March 10, 2004

Alrex safe for long-term treatment of seasonal allergic conjunctivitis

Feb. 24, 2004

Senju claims new chymase and/or tryptase inhibitors and their use

Feb. 11, 2004

Extension to Vitrase NDA review

Feb. 10, 2004

Inspire to conduct additional trial for diquafosol following FDA meeting

Feb. 4, 2004

Phase III data for a fixed travoprost/timolol combination in glaucoma

Jan. 29, 2004

Novel EP4 agonists with utility in glaucoma and bone disorders

Jan. 23, 2004

Santen and Asahi Glass claim new prostaglandin analogues for glaucoma and other ocular disorders

Jan. 22, 2004

AFP-168, a novel ocular hypotensive candidate

Jan. 20, 2004

International pivotal Trabio study completes enrollment

Jan. 14, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...